{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=17", "query": { "condition": "Non-Small Cell Lung Cancer, Small Cell Lung Cancer", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 3662, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:11:43.262Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05920356", "title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 750, "start_date": "2023-11-16", "completion_date": "2032-06-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 30, "location_summary": "Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 25 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05920356" }, { "nct_id": "NCT03924869", "title": "Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2019-06-25", "completion_date": "2025-01-20", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03924869" }, { "nct_id": "NCT04000529", "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Esophageal SCC", "Gastrointestinal Stromal Tumors", "Colorectal Cancer" ], "interventions": [ { "name": "TNO155", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2019-07-30", "completion_date": "2024-01-15", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04000529" }, { "nct_id": "NCT02029729", "title": "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic or Incurable Non-small Cell Lung Cancer", "Relapsed, Refractory Melanoma" ], "interventions": [ { "name": "omaveloxolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2013-12-31", "completion_date": "2015-10-01", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029729" }, { "nct_id": "NCT05462795", "title": "Liquid Biopsy for Early Non-small Lung Cancer Detection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small-cell Lung Cancer" ], "interventions": [ { "name": "Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule", "type": "DIAGNOSTIC_TEST" }, { "name": "Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection", "type": "DIAGNOSTIC_TEST" }, { "name": "Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer", "type": "DIAGNOSTIC_TEST" }, { "name": "Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2022-08-02", "completion_date": "2024-03-22", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462795" }, { "nct_id": "NCT04638751", "title": "ARGONAUT: Stool and Blood Sample Bank for Cancer Patients", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Pancreas Cancer" ], "interventions": [ { "name": "Immunotherapy", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "CRC surgical resection", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Persephone Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2022-07-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 10, "location_summary": "Orange, California • San Diego, California • Miami, Florida + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04638751" }, { "nct_id": "NCT07023731", "title": "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12D Mutation", "Advanced Solid Cancer" ], "interventions": [ { "name": "ARV-806", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-05-29", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 14, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07023731" }, { "nct_id": "NCT02186301", "title": "TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Rociletinib Mono-Therapy", "type": "DRUG" }, { "name": "Erlotinib Mono-Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2014-11", "completion_date": "2017-06-28", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Burbank, California • Duarte, California + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186301" }, { "nct_id": "NCT05256381", "title": "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Cutaneous Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Castration-resistant Prostate Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Nanrilkefusp Alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOTIO Biotech AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2022-06-21", "completion_date": "2024-11-29", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 2, "location_summary": "Whittier, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05256381" }, { "nct_id": "NCT02584634", "title": "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "PF-06463922", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-12-18", "completion_date": "2022-07-13", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-10-15T12:11:43.262Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584634" } ] }